Leukemia

Combination ivosidenib/azacitidine has yielded notable improvements in survival over ivosidenib alone in IDH1-positive treatment-naïve acute myeloid leukemia.

Older adult patients with newly diagnosed high-risk or secondary acute myeloid leukemia experienced a durable survival benefit when treated with CPX-351 over 7+3 cytarabine and daunorubicin chemotherapy.

The SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab for patients with treatment-naïve chronic lymphocytic leukemia demonstrated superior progression-free survival results with the BTK inhibitor.

Patients with Philadelphia chromosome–negative acute lymphocytic leukemia who have hypersensitivity to pegylated asparaginase may benefit from eryaspase treatment.

A phase 1/2 trial featuring lanraplenib/gilteritinib in patients with FLT3-mutant acute myeloid leukemia will proceed following the FDA’s clearance of an investigational new drug application.

Results of a phase 2 trial show that ibrutinib was capable of inducing responses in some patients with hairy cell leukemia who were previously treated with standard therapy options in a prior line.

The phase 2 GIMEMA LAL1913 trial identified poor outcomes and increased minimal residual disease persistence among patients with Philadelphia-like acute lymphoblastic leukemia.

A new study has adapted CAR to look more human to the body, which will then in turn yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

The updated results of an ongoing phase 1/2 study indicated that CA-4948 achieved promising responses and a tolerable safety profile in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

In a trial of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and other hematologic cancers, the BCL-2 inhibitor lisaftoclax demonstrated feasibility as a treated option in the relapsed or refractory setting.

Ibrutinib and venetoclax may prove beneficial in previously untreated chronic lymphocytic leukemia.

Update from a preplanned clinical trial analysis shows promise of devimistat in relapsed/refractory acute myeloid leukemia.

Approval of asparaginase erwinia chrysanthemi (recombinant)-rywn represents a long-awaited alternative to E. Coli–derived asparaginase for patients with acute lymphoblastic leukemia.

SNDX-5613 has received a fast track designation from the FDA for the treatment of relapsed/refractory acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia.

CYNK-001, a human placental hematopoietic stem cell–derived natural killer cell infusion, will now be tested in an expanded population following promising results in a phase 1 trial.

Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.

All patients with chronic lymphocytic leukemia who were treated with zanubrutinib in the relapsed/refractory setting showed impressive responses.

A trial of an eprenetapopt combination has met the prespecified primary efficacy end point in patients with acute myeloid leukemia harboring TP53 mutations.

Results of the phase 1 portion of ZUMA-4 support continued investigation into the efficacy of KTE-X19 in pediatric patients with B-cell acute lymphoblastic leukemia.

Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.

A progression-free survival advantage persisted at the 3-year mark with venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

The risk of progression or death was statistically significantly reduced with the use of ibrutinib and venetoclax versus chlorambucil plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.

Data presented at 2021 ASCO indicated that chimeric antigen receptor therapy with ALLO-501A plus ALLO-647 lymphodepletion showed promise in patients with relapsed/refractory large B-cell lymphoma.

Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.

Data from EHA 2021 showed that zanubrutinib was associated with better outcomes over ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma